[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643368":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":43,"collaborators":20,"id":47,"slug":20,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":20,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":20,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":20,"overallStatus":29,"whyStopped":20,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Shanghai Mental Health Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Bilateral Amygdala Group (BLA-TI)","EXPERIMENTAL","Open-label, single-arm. Participants receive active Temporal Interference (TI) stimulation targeting the bilateral amygdala. Stimulation is delivered twice daily (20 minutes per session) for 7 consecutive days. Parameters: carrier frequencies 2000 Hz and 2160 Hz, envelope frequency 160 Hz, intensity 3-4 mA (adjusted to individual tolerance). Target localization is performed using each participant's MRI data to construct an individualized 3D head model, generating scalp stimulation coordinates for the bilateral amygdala.",[13],"Device: TI stimulation device (nerviox-1000）",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","TI stimulation device (nerviox-1000）","The TI stimulation device delivers temporally interfering electrical fields with a 160 Hz envelope frequency, generated by high-frequency carrier waves (2000 Hz and 2160 Hz). Stimulation is applied for 20 minutes per session, with a peak current of 3-4 mA per channel, adjusted based on individual tolerance. The stimulation target is the bilateral amygdala. Stimulation is administered twice daily, with the treatment phase lasting 7 consecutive days.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Zhen Wang, PhD,MD","CONTACT","+86 34773516","wangzhen@smhc.org.cn",[28],{"facility":5,"status":29,"city":30,"state":20,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Shanghai","200030","China","CN",{"type":35,"coordinates":36},"Point",[37,38],121.45806,31.22222,{"lat":38,"lon":37},[41],{"name":42,"role":24,"phone":25,"phoneExt":20,"email":26},"Zhen Wang, Phd, MD",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Zhen Wang","vice-president","100643368",false,"NCT07644338","The Efficacy and Safety of Temporal Interference Stimulation in the Treatment of Post-Traumatic Stress Disorder","Inclusion Criteria:\n\n1. Age 18-50 years, male or female\n2. Diagnosis of PTSD per DSM-5 (assessed by CAPS-5), with symptom duration of at least 3 months, and PTSD as the current primary diagnosis; comorbid depressive disorder or anxiety disorder is allowed\n3. If currently receiving psychiatric medication, the dosage must be stable for at least 4 weeks prior to enrollment\n4. At least 9 years of education (junior high school or above)\n\nExclusion Criteria:\n\n1. Any DSM-5 diagnosis other than PTSD, depressive disorder, or anxiety disorder\n2. PTSD symptoms too severe to complete required assessments\n3. Received electroconvulsive therapy (ECT) within the past 6 months\n4. Received any other form of neuromodulation within the past 2 months (see Item 3 for ECT)\n5. Severe medical illness or any condition that may induce seizures or intracranial hypertension (e.g., cardiovascular or respiratory diseases)\n6. History of neurological disorders (e.g., epilepsy, cerebrovascular accident) or brain injury\u002Fsurgery\n7. Presence of intracranial stents, cardiac pacemakers, coronary stents, cochlear implants, or any other MRI-incompatible implants\n8. Current significant suicidal behavior risk per investigator judgment\n9. Pregnancy or planning to become pregnant during the study period\n10. Initiation of structured psychotherapy for PTSD within 3 months prior to screening, with expected change during the 10-week treatment period","ALL","18 Years","50 Years",{"count":56,"type":57},5,"ESTIMATED","INTERVENTIONAL",[60],"NA","This study aims to evaluate the efficacy and safety of Temporal Interference (TI) stimulation in treating patients with post-traumatic stress disorder (PTSD) and to explore its potential neural mechanisms using magnetic resonance imaging (MRI) ,magnetoencephalography（MEG）,electroencephalography (EEG).",[63],"Post-traumatic Stress Disorder (PTSD)","2026-06-08",{"date":66,"type":67},"2026-06-12","ACTUAL",{"date":64,"type":67},{"date":70,"type":57},"2027-06",{"name":5,"class":6},1]